Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project
Small Molecules Identified for Therapeutic Intervention in Oncology and Inflammation
Edinburgh, Scotland, and Villigen, Switzerland, 20 August 2024: Europe’s rst oncology-focused biotech creation company, announces that, in parnership with its collaborator leadXpro (LXP), key milestones have been achieved in their protein structure driven GPR68 drug discovery project. As a result, Cumulus has licensed the small molecule compounds and associated IP created during this collaboration and will continue the programme to lead optimisation and beyond.
